Grants per year
Personal profile
Research Interests
The overarching goal of our scientific work has been to define key molecular pathways in the pathogenesis of neurodegeneration and to uncover novel targets for therapeutic development. We have focused on pathogenic mechanisms that are commonly altered in neurodegenerative disorders such as deficient degradation of aggregation-prone proteins and mitochondrial dysfunction. As a general strategy, we study rare genetic diseases with mutations in genes that play a role in these key mechanisms and pathways. Models of Huntington’s, Parkinson’s and Gaucher’s disease have been utilized to examine if activation of cellular degradation pathways can lead to neuroprotection. To validate and study these findings in human neurons, we utilize induced pluripotent stem cells (iPS) generated by reprogramming of patient-specific skin fibroblasts. These iPS cells are differentiated into specific neuronal subtypes in order to characterize the interplay of genetic, epigenetic and environmental factors in disease pathogenesis. The ultimate goal of these studies is to develop targeted therapies for Parkinson’s and related neurodegenerative disorders.
Certifications and Licenses
| Neurology |
Training Experience
| 2000 | Residency, Massachusetts General Hospital and Brigham and Women’s Hospital, Harvard Medical School |
| 2002 | Fellowship, Massachusetts General Hospital, Harvard Medical School |
Education/Academic qualification
MD, University of Zagreb
… → 1992
Research interests
- Aging
- Alzheimer's Disease
- Gene Regulation
- Movement Disorders
- Neurogenetics
- Neurology
- Neuroscience
- Parkinson’s Disease
Fingerprint Dive into the research topics where Dimitri Krainc is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 12 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants
2019 and 2020 – Parkinson's Foundation Institutional MDS Training Award
Krainc, D., Mencacci, N. E., Simuni, T. & Zadikoff, C.
7/1/19 → 6/30/21
Project: Research project
Convergence of LRRK2 and GBA1 in the pathogenesis of Parkinson' Disease
Michael J. Fox Foundation for Parkinson's Research
6/10/19 → 6/9/21
Project: Research project
Genotype-phenotype analysis and therapeutic development for Parkinson’s disease
2/1/18 → 2/1/21
Project: Research project
Research Output
Author Correction: Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain (Nature Neuroscience, (2020), 23, 1, (15-20), 10.1038/s41593-019-0556-3)
Graves, S. M., Xie, Z., Stout, K. A., Zampese, E., Burbulla, L. F., Shih, J. C., Kondapalli, J., Patriarchi, T., Tian, L., Brichta, L., Greengard, P., Krainc, D., Schumacker, P. T. & Surmeier, D. J., Feb 1 2020, In : Nature Neuroscience. 23, 2, 1 p.Research output: Contribution to journal › Comment/debate
Open Access
Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain
Graves, S. M., Xie, Z., Stout, K. A., Zampese, E., Burbulla, L. F., Shih, J. C., Kondapalli, J., Patriarchi, T., Tian, L., Brichta, L., Greengard, P., Krainc, D., Schumacker, P. T. & Surmeier, D. J., Jan 1 2020, In : Nature neuroscience. 23, 1, p. 15-20 6 p.Research output: Contribution to journal › Article
2
Scopus
citations
A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson’s disease
Burbulla, L. F., Jeon, S., Zheng, J., Song, P., Silverman, R. B. & Krainc, D., Oct 16 2019, In : Science translational medicine. 11, 514, eaau6870.Research output: Contribution to journal › Article
4
Scopus
citations
Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase
Zheng, J., Jeon, S., Jiang, W., Burbulla, L. F., Ysselstein, D., Oevel, K., Krainc, D. & Silverman, R. B., Feb 14 2019, In : Journal of Medicinal Chemistry. 62, 3, p. 1218-1230 13 p.Research output: Contribution to journal › Article
4
Scopus
citations
Correction to: Conversion of quinazoline modulators from inhibitors to activators of β-glucocerebrosidase (Journal of Medical Chemistry (2019) 62: 3 (1218-1230) DOI: 10.1021/acs.jmedchem.8b01294)
Zheng, J., Jeon, S., Jiang, W., Burbulla, L. F., Ysselstein, D., Oevel, K., Krainc, D. & Silverman, R. B., Mar 14 2019, In : Journal of Medicinal Chemistry. 62, 5, 1 p.Research output: Contribution to journal › Comment/debate